Drugs / Omega 3 PUFA
Omega 3 PUFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01953705 | May 2014 → Dec 2020 | Alzheimer disease, subjective cognitive decline, vascular dementia | Oregon Health and Science University | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega 3 PUFA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01953705 ↗ |
| Known as | marine n-3 polyunsaturated fatty acids | “either marine n-3 polyunsaturated fatty acids (n-3 PUFA) or soybean oil placebo” PMID 30934894 ↗ Mar 2019 |
| Known as | n-3 PUFA | “either marine n-3 polyunsaturated fatty acids (n-3 PUFA) or soybean oil placebo” PMID 30934894 ↗ Mar 2019 |
| Known as | ω-3 PUFA | “Three-year treatment with 1.65 g of ω-3 PUFA (975 mg of EPA and 650 mg of DHA) vs a soybean oil placebo matched for taste, smell, and appearance” PMID 39088212 ↗ Aug 2024 |